Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction,...

연구 요약

Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy Adults.

Clinical pharmacology in drug development 학술지에 발표된 이 연구는 Polasek TM, Paneliya KJ, Lin T 외 연구팀이 수행하였습니다.

이 연구는 'Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy Adults.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Tinlarebant is an oral retinol binding protein 4 antagonist in clinical development for geographic atrophy, an advanced stage of dry age-related macular degeneration, and Stargardt disease, an inherited juvenile-onset macular degeneration. A randomized, open-label, two-period, interaction study in healthy adults was conducted in four parts to determine the effects of gastric acid suppression (omeprazole 40 mg QD), cytochrome P4503A (CYP3A) inhibition (itraconazole 200 mg BD) and induction (rifampin 600 mg QD), and food on the pharmacokinetics of tinlarebant (5 mg single dose). The effects on tinlarebant exposure were quantified by geometric least squares (GLS) mean Cmax and AUCinf ratios, where GLS mean Cmax or AUCinf with potential perpetrator is divided by GLS mean Cmax or AUCinf without potential perpetrator. Steady-state dosing of omeprazole had no effect on tinlarebant exposure (Cmax ratio = 1.16 and AUCinf ratio = 1.03). The Cmax and AUCinf ratios of tinlarebant following itraconazole dosing were 1.29 and 2.42, respectively. Rifampin co-administration decreased tinlarebant Cmax and AUCinf ratios to 0.53 and 0.19, respectively. Compared with the fasting state, taking tinlarebant with food gave Cmax and AUCinf ratios in the range 1.08-1.22. No unexpected safety signals occurred and tinlarebant was well tolerated in all participants. These data show that the pharmacokinetics of tinlarebant is not significantly altered by gastric acid suppression or food. Dosing patients with tinlarebant and strong CYP3A inhibitors is unlikely to compromise safety based on its pharmacokinetic-pharmacodynamic relationships, but tinlarebant should be contraindicated with strong CYP3A inducers due to potential treatment failure.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41545331)